Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Impact Biomedical Q3 2026 Results: Net Loss of $645K, Loss Narrows

Impact BioMedical reported a net loss of $3.63 million for the nine months ended September 30, 2026, a significant improvement from the $17.11 million loss in the prior year period which was driven by a $13.21 million change in fair value of a related party note. The company maintains a minimal revenue base of $31,000 and continues to focus on developing its proprietary healthcare technologies like Linebacker™.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.00.0
Profit before tax-0.6-1.5
Net income-0.6-1.5
EPS (diluted, $ a share)$-0.08$-1.52

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+16.7%
Source

10-Q filed with the SEC, NYSE: IBO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Impact Biomedical Inc.: key numbers

Share price
$4.91Close, Nov 16
Market cap
$42.4M
Shares outstanding
8.64MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Impact Biomedical Inc.

All →
9:15 AM ET 8-K
M&A Deal

Impact Biomedical M&A Deal with Zoar Limited

Impact Biomedical Inc. announced that the SEC has declared effective the Form F-4 registration statement for its proposed merger with Zoar Limited. A special meeting of stockholders to approve the business combination is scheduled for November 13, 2026, with the combined company expected to trade under the ticker symbol 'ZOAR'.

Counterparty
Zoar Limited
4:59 PM ET 8-K
Reverse Stock Split

Impact Biomedical Reverse Stock Split

Impact BioMedical Inc. implemented a 1-for-12.62 reverse stock split of its common stock effective September 23, 2026. The split reduced the number of outstanding shares from approximately 107.8 million to 8.6 million to adjust the company's capital structure. The stock began trading on a split-adjusted basis on the NYSE American under the existing ticker symbol 'IBO'.

6:01 AM ET 8-K
M&A Deal

Impact Biomedical M&A Deal with Zoar Limited

Impact Biomedical Inc. announced the filing of a Form F-4 registration statement by Zoar Limited in connection with their previously announced business combination. The filing represents a major milestone toward closing the merger, which will result in a combined pharmaceutical company focused on active pharmaceutical ingredients and special therapeutic treatments. The transaction remains subject to SEC effectiveness, stockholder approval, and NYSE American listing approval.

Counterparty
Zoar Limited
6:04 AM ET 8-K
Reverse Stock Split

Impact Biomedical Reverse Stock Split

Impact Biomedical Inc. announced a 1-for-12.62 reverse stock split effective September 23, 2026, reducing outstanding shares from approximately 107.8 million to 8.5 million. The split is intended to regain compliance with NYSE American listing requirements and facilitate its proposed merger with Zoar Limited. Following the split and merger closing, Impact stockholders are expected to receive one share of Zoar Limited for every one share of Impact common stock held.

Counterparty
Zoar Limited

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.